Brought to you by:
Equivalent outcomes seen among female, male patients in real-world analysis of paclitaxel-eluting stent use
The use of a paclitaxel-eluting stent to treat femoropopliteal occlusive disease led to equivalent outcomes in male and female patients in “a diverse and complex real-world cohort,” a new study found, set against previous question marks over the effectiveness of…
UK MHRA update: Paclitaxel-coated device increased mortality risk is withdrawn for PAD
Following a review, the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has updated guidance on the use of paclitaxel-coated devices stating that such devices can be considered for the treatment of peripheral arterial disease (PAD), including intermittent claudication and critical…
The top 10 most popular Vascular Specialist stories of July 2023
In the previous month, Vascular Specialist delivered a range of leading commentary from the Society for Vascular Surgery (SVS) in response to the New York Times investigation on inappropriateness in vascular care; the anticipated Food and Drug Administration (FDA) update…
Paclitaxel DCB performs well in ‘challenging anatomy’ of femoropopliteal in-stent restenosis, VQI registry data show
The IN.PACT Admiral drug-coated balloon (DCB) shows promising results in treating femoropopliteal in-stent restenosis (ISR) in a Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) registry-based, postmarket surveillance study. This is according to Daniel Bertges, MD, a vascular surgeon…
PCBs: Panel of vascular surgeons review latest findings on paclitaxel-coated balloons
A recent meta-analysis by Konstantinos Katsanos, MD, of Patras University Hospital, Rion, Greece, and colleagues—“Risk of major amputation following application of paclitaxel-coated balloons [PCBs] in the lower-limb arteries: A systematic review and meta-analysis of randomized controlled trials [RCTs],” published in…
VAM discussion on latest paclitaxel meta-analysis yields mix of caution, skepticism
A Vascular Annual Meeting (VAM) sponsored session on paclitaxel safety drew a mix of skeptical and cautious responses to the latest meta-analysis from interventional radiologist Konstantinos Katsanos, MD, that reported a heightened risk of major amputation after use of paclitaxel-coated balloons…
Latest meta-analysis on paclitaxel in peripheral arterial disease provokes mixed reception
“There appears to be heightened risk of major amputation after use of paclitaxel-coated balloons [PCBs] in the peripheral arteries,” findings from a systematic review and meta-analysis of randomized controlled trials (RCTs) published in the European Journal of Vascular and Endovascular…
Veterans study: No evidence of increased risk of death with use of PCDs out to three years
A study of more than 10,000 U.S. veterans with peripheral arterial disease (PAD) undergoing endovascular interventions in the femoropopliteal segment found that rates of two‐ and three‐year all‐cause mortality were similar among patients undergoing revascularization with a paclitaxel-coated device (PCD)…
LINC 2021: Long-term data show sustained efficacy and safety of paclitaxel devices in fempop lesions
A key theme among the late-breaking trial data presented at the recent LINC 2021 (the Leipzig Interventional Course), held digitally from Jan. 25–29, was the emergence of long-term evidence on paclitaxel devices in the femoropopliteal segment. Results out to five years shows…
‘Ample published data unable to replicate association between paclitaxel-coated devices and mortality’
Ample published data from from large, observational datasets, randomized-controlled trial (RCT) subgroup analyses and long-term follow-up from pivotal paclitaxel-coated device RCTs have not been able to replicate an association between such devices and mortality, an expert analysis recently published online…